COMPASS Pathways to Announce Q1 Earnings on May 13
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 45 minutes ago
0mins
Should l Buy CMPS?
Source: seekingalpha
- Earnings Announcement: COMPASS Pathways ADS (CMPS) is set to announce its Q1 2023 earnings on May 13 before market open, with a consensus EPS estimate of -$0.45, indicating ongoing challenges in profitability.
- Earnings Estimate Changes: Over the past three months, EPS estimates have seen one upward revision and no downward adjustments, reflecting a cautiously optimistic outlook from analysts regarding COMPASS Pathways' future performance, despite the overall negative expectation.
- Market Outlook: The company has reported positive Phase III results for its psilocybin asset in treatment-resistant depression trials, suggesting significant potential value in the mental health sector, which could lay the groundwork for future growth.
- Industry Developments: With Trump signing legislation to expedite PTSD research, COMPASS Pathways is positioned strongly in the rapidly evolving psychedelic market, particularly with its upcoming psychedelic filing, which may attract increased investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.650
Low
8.00
Averages
18.43
High
40.00
Current: 9.650
Low
8.00
Averages
18.43
High
40.00
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
COMPASS Pathways to Announce Q1 Earnings on May 13
- Earnings Announcement: COMPASS Pathways ADS (CMPS) is set to announce its Q1 2023 earnings on May 13 before market open, with a consensus EPS estimate of -$0.45, indicating ongoing challenges in profitability.
- Earnings Estimate Changes: Over the past three months, EPS estimates have seen one upward revision and no downward adjustments, reflecting a cautiously optimistic outlook from analysts regarding COMPASS Pathways' future performance, despite the overall negative expectation.
- Market Outlook: The company has reported positive Phase III results for its psilocybin asset in treatment-resistant depression trials, suggesting significant potential value in the mental health sector, which could lay the groundwork for future growth.
- Industry Developments: With Trump signing legislation to expedite PTSD research, COMPASS Pathways is positioned strongly in the rapidly evolving psychedelic market, particularly with its upcoming psychedelic filing, which may attract increased investor interest.
See More
Compass Pathways to Release Q1 Financial Results on May 13, 2026
- Earnings Release Schedule: Compass Pathways plc will announce its financial results for the first quarter ended March 31, 2026, on May 13, 2026, providing updates on recent developments that are expected to positively impact investor confidence.
- Conference Call Timing: Management will host a conference call at 8:00 am ET (1:00 pm UK) to discuss financial performance and future strategies, aiming to enhance market transparency and investor engagement.
- Webcast Availability: The call will be available via live webcast on the Compass Pathways website, with the recording archived for 30 days, ensuring that investors who cannot attend live can still access critical information, thereby improving information dissemination.
- Innovative Treatment Solutions: The COMP360 synthesized psilocybin treatment has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression, highlighting the company's leading position in this area and potentially attracting more investor interest.
See More
COMPASS PATHWAYS PLC: JEFFERIES BEGINS COVERAGE WITH A BUY RATING AND TARGET PRICE OF $18
Company Overview: Compass Pathways PLC is a mental health care company focused on developing innovative treatments for mental health conditions.
Recent Developments: The company has received coverage with a buy rating, indicating positive investor sentiment and confidence in its future performance.
Target Price: Analysts have set a target price of $18 for Compass Pathways shares, suggesting potential growth in value.
Market Position: The company's initiatives and market strategies are aimed at addressing significant unmet needs in mental health treatment.
See More
CMPS Stock Surges 41% This Week, Poised for Record Gains
- FDA Priority Review: Compass Pathways' COMP360 has been granted the Commissioner's National Priority Voucher by the FDA, allowing for a dramatically shortened review period of 1-2 months for its treatment-resistant depression application, thereby accelerating the market entry of this innovative therapy and enhancing the company's competitive edge.
- Analyst Ratings Optimistic: According to Koyfin, 11 out of 12 analysts covering CMPS rate it 'Buy' or higher, indicating strong market confidence in COMP360, with a projected 141% upside potential, which is likely to attract further investor interest.
- Strong Stock Performance: CMPS stock has surged 45% this week, with an additional 5.5% increase on Friday, marking the best week in the company's history and reflecting positive market expectations for its drug development, potentially drawing more capital inflows.
- High Market Sentiment: On Stocktwits, retail investor sentiment around CMPS remains in the 'extremely bullish' territory with extremely high message volume, indicating a strong optimistic outlook among investors regarding the company's future developments, further fueling the stock's rise.
See More
Compass Secures FDA Priority Review Support for COMP360
- FDA Priority Review: Compass Pathways has received a rolling NDA submission and review request from the FDA based on positive data from two large Phase 3 clinical trials, marking a significant advancement in the treatment of treatment-resistant depression and potentially accelerating its product launch timeline.
- National Priority Voucher Program: COMP360 has been selected for the FDA's National Priority Voucher program, which allows for a shortened review time of 1-2 months, enhancing Compass's market competitiveness and providing patients with quicker access to innovative treatment options that are urgently needed.
- Clinical Trial Results: COMP360 has demonstrated significant clinical effects in over 1,000 patients with treatment-resistant depression, showing effects as quickly as one day after administration, with durability lasting at least six months for those achieving a clinically meaningful response, offering new hope for patients.
- Urgent Market Demand: With approximately 4 million patients in the U.S. affected by treatment-resistant depression, Compass's innovative treatment could not only improve quality of life for these individuals but also potentially become the first breakthrough therapy in this field, addressing the growing market demand.
See More
COMP360 Receives FDA Priority Review Voucher
- FDA Priority Review: COMPASS Pathways' COMP360 has received an FDA Commissioner's National Priority Voucher, allowing for a review period of one to two months post-NDA submission, significantly shortening the approval timeline and enhancing market competitiveness.
- Rolling Submission Approval: The FDA has granted COMPASS Pathways' request for a rolling submission, enabling the company to submit data incrementally during the NDA process, thereby accelerating communication with the FDA and optimizing the approval workflow.
- Clinical Trial Success: In February, COMP360 achieved its primary endpoint in a late-stage trial, demonstrating its efficacy in treating treatment-resistant depression, which lays a solid foundation for future market launch efforts.
- Positive Market Outlook: As a leader in the psychedelic market, COMPASS Pathways is expected to attract increased investor interest following the FDA's favorable feedback and successful clinical trials, likely driving the company's stock price upward.
See More
COMPASS Pathways to Announce Q1 Earnings on May 13
- Earnings Announcement: COMPASS Pathways ADS (CMPS) is set to announce its Q1 2023 earnings on May 13 before market open, with a consensus EPS estimate of -$0.45, indicating ongoing challenges in profitability.
- Earnings Estimate Changes: Over the past three months, EPS estimates have seen one upward revision and no downward adjustments, reflecting a cautiously optimistic outlook from analysts regarding COMPASS Pathways' future performance, despite the overall negative expectation.
- Market Outlook: The company has reported positive Phase III results for its psilocybin asset in treatment-resistant depression trials, suggesting significant potential value in the mental health sector, which could lay the groundwork for future growth.
- Industry Developments: With Trump signing legislation to expedite PTSD research, COMPASS Pathways is positioned strongly in the rapidly evolving psychedelic market, particularly with its upcoming psychedelic filing, which may attract increased investor interest.
See More
Compass Pathways to Release Q1 Financial Results on May 13, 2026
- Earnings Release Schedule: Compass Pathways plc will announce its financial results for the first quarter ended March 31, 2026, on May 13, 2026, providing updates on recent developments that are expected to positively impact investor confidence.
- Conference Call Timing: Management will host a conference call at 8:00 am ET (1:00 pm UK) to discuss financial performance and future strategies, aiming to enhance market transparency and investor engagement.
- Webcast Availability: The call will be available via live webcast on the Compass Pathways website, with the recording archived for 30 days, ensuring that investors who cannot attend live can still access critical information, thereby improving information dissemination.
- Innovative Treatment Solutions: The COMP360 synthesized psilocybin treatment has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression, highlighting the company's leading position in this area and potentially attracting more investor interest.
See More
COMPASS PATHWAYS PLC: JEFFERIES BEGINS COVERAGE WITH A BUY RATING AND TARGET PRICE OF $18
Company Overview: Compass Pathways PLC is a mental health care company focused on developing innovative treatments for mental health conditions.
Recent Developments: The company has received coverage with a buy rating, indicating positive investor sentiment and confidence in its future performance.
Target Price: Analysts have set a target price of $18 for Compass Pathways shares, suggesting potential growth in value.
Market Position: The company's initiatives and market strategies are aimed at addressing significant unmet needs in mental health treatment.
See More
CMPS Stock Surges 41% This Week, Poised for Record Gains
- FDA Priority Review: Compass Pathways' COMP360 has been granted the Commissioner's National Priority Voucher by the FDA, allowing for a dramatically shortened review period of 1-2 months for its treatment-resistant depression application, thereby accelerating the market entry of this innovative therapy and enhancing the company's competitive edge.
- Analyst Ratings Optimistic: According to Koyfin, 11 out of 12 analysts covering CMPS rate it 'Buy' or higher, indicating strong market confidence in COMP360, with a projected 141% upside potential, which is likely to attract further investor interest.
- Strong Stock Performance: CMPS stock has surged 45% this week, with an additional 5.5% increase on Friday, marking the best week in the company's history and reflecting positive market expectations for its drug development, potentially drawing more capital inflows.
- High Market Sentiment: On Stocktwits, retail investor sentiment around CMPS remains in the 'extremely bullish' territory with extremely high message volume, indicating a strong optimistic outlook among investors regarding the company's future developments, further fueling the stock's rise.
See More
Compass Secures FDA Priority Review Support for COMP360
- FDA Priority Review: Compass Pathways has received a rolling NDA submission and review request from the FDA based on positive data from two large Phase 3 clinical trials, marking a significant advancement in the treatment of treatment-resistant depression and potentially accelerating its product launch timeline.
- National Priority Voucher Program: COMP360 has been selected for the FDA's National Priority Voucher program, which allows for a shortened review time of 1-2 months, enhancing Compass's market competitiveness and providing patients with quicker access to innovative treatment options that are urgently needed.
- Clinical Trial Results: COMP360 has demonstrated significant clinical effects in over 1,000 patients with treatment-resistant depression, showing effects as quickly as one day after administration, with durability lasting at least six months for those achieving a clinically meaningful response, offering new hope for patients.
- Urgent Market Demand: With approximately 4 million patients in the U.S. affected by treatment-resistant depression, Compass's innovative treatment could not only improve quality of life for these individuals but also potentially become the first breakthrough therapy in this field, addressing the growing market demand.
See More
COMP360 Receives FDA Priority Review Voucher
- FDA Priority Review: COMPASS Pathways' COMP360 has received an FDA Commissioner's National Priority Voucher, allowing for a review period of one to two months post-NDA submission, significantly shortening the approval timeline and enhancing market competitiveness.
- Rolling Submission Approval: The FDA has granted COMPASS Pathways' request for a rolling submission, enabling the company to submit data incrementally during the NDA process, thereby accelerating communication with the FDA and optimizing the approval workflow.
- Clinical Trial Success: In February, COMP360 achieved its primary endpoint in a late-stage trial, demonstrating its efficacy in treating treatment-resistant depression, which lays a solid foundation for future market launch efforts.
- Positive Market Outlook: As a leader in the psychedelic market, COMPASS Pathways is expected to attract increased investor interest following the FDA's favorable feedback and successful clinical trials, likely driving the company's stock price upward.
See More
